MaxCyte Inc.
MXCT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MXCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MXCT
MaxCyte Inc. (MXCT) is a cell-engineering technology company that provides its Flow Electroporation platform to biopharma partners for developing cell-based therapies, with a focus on ex-vivo cell therapy manufacturing.
Key risk: Ongoing operating losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
MaxCyte Inc. (MXCT) is a cell-engineering technology company that provides its Flow Electroporation platform to biopharma partners for developing cell-based therapies, with a focus on ex-vivo cell therapy manufacturing.
- As of June 30, 2026, MaxCyte had cash & equivalents of $15.0M and total revenue of $7.3M, with a net loss of -$8.9M [sec].
- The company's customer base includes 29 Strategic Platform License (SPL) partners and a majority of the top 25 pharmaceutical companies based on 2025 global revenue [sec_mda · as of 2026-08-13].
- MaxCyte's Flow Electroporation technology is used by an SPL partner to engineer the first ex-vivo cell therapy approved by the FDA in December 2023 [sec_mda · as of 2026-08-13].
- The company has incurred significant operating losses since inception, with an accumulated deficit of $261.5M as of December 31, 2025 [sec_mda · as of 2026-03-25].
- MaxCyte generated revenue of $16.9M and a net loss of $13.6M for the six months ended June 30, 2026 [sec_mda · as of 2026-08-13].
What works
- MaxCyte's Flow Electroporation technology is used in the first FDA-approved ex-vivo cell therapy, demonstrating clinical and regulatory validation [sec_mda · as of 2026-08-13].
- The company has a broad customer base including 29 SPL partners and a majority of the top 25 global pharma companies, indicating strong industry adoption [sec_mda · as of 2026-08-13].
- MaxCyte has placed over 857 electroporation instruments worldwide as of December 31, 2025, showing commercial traction [sec_mda · as of 2026-03-25].
What to weigh
- MaxCyte has incurred significant operating losses since inception, with an accumulated deficit of $261.5M as of December 31, 2025 [sec_mda · as of 2026-03-25].
- The company's revenue of $7.3M for the six months ended June 30, 2026 is modest relative to its net loss of -$8.9M, indicating ongoing cash burn [sec].
- MaxCyte's future funding requirements depend on factors such as market acceptance and R&D costs, and it may need additional capital sooner than expected [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
MaxCyte's technology is used in the first FDA-approved ex-vivo cell therapy.
“Our Flow Electroporation technology is used by one of our SPL partners to engineer the first ex-vivo cell therapy approved by the FDA in December 2023.”
SEC MD&A · August 13, 2026
MaxCyte has 29 SPL partners and serves a majority of top pharma companies.
“30, 2026, our customer base includes 29 Strategic Platform License ("SPL") partners, a majority of the top 25 pharmaceutical companies based on 2025 global revenue, hundreds of biotechnology companies and academic research centers.”
SEC MD&A · August 13, 2026
MaxCyte's revenue and net loss for the first half of 2026.
“We generated revenue of $16.9 million and incurred a net loss of $13.6 million for the six months ended June 30, 2026.”
SEC MD&A · August 13, 2026
Risks & what to watch (3)›
Key risks
- Ongoing operating losses — MaxCyte has incurred net losses since inception, with an accumulated deficit of $261.5M as of Dec 31, 2025 [sec_mda · as of 2026-03-25].
- Dependence on partner adoption — Revenue depends on market acceptance of its products and the success of SPL partners' cell therapies [sec_mda · as of 2026-08-13].
- Capital requirements uncertainty — The company may need additional funding sooner than expected if assumptions about cash runway prove wrong [sec_mda · as of 2026-08-13].
What to watch
- Progress of SPL partners' cell therapy programs, especially those using MaxCyte's technology in clinical trials [sec_mda · as of 2026-08-13].
- Changes in cash position and cash runway, given the company's ongoing net losses and reliance on external funding [sec].
- Adoption of Flow Electroporation by additional biopharma partners and expansion of the installed base of instruments [sec_mda · as of 2026-03-25].
- Regulatory milestones for partner therapies, as FDA approvals could drive further revenue from license fees and royalties [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 18, 2026 · How we verify sources →
Run MaxCyte Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MaxCyte Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
68.1 months
D/E 0.16 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
127
Total value held
$38.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,798,473 | $6.2M |
| vanguard capital management llc | 7,963,632 | $5.6M |
| vitruvian partners llp | 5,043,356 | $3.5M |
| morgan stanley | 3,688,131 | $2.6M |
| bnp paribas asset management holding s.a. | 2,773,554 | $1.9M |
| geode capital management, llc | 2,362,672 | $1.7M |
| state street corp | 2,193,470 | $1.5M |
| renaissance technologies llc | 1,993,200 | $1.4M |
| cadian capital management, lp | 1,722,942 | $1.2M |
| peapod lane capital llc | 1,332,193 | $926K |
Showing top 10 of 127 institutional holders of MaxCyte Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 5.2%
- Days to cover
- 5.4
- Shares short
- 5,552,543
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MXCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for MaxCyte Inc.?
MaxCyte Inc. (MXCT) is a cell-engineering technology company that provides its Flow Electroporation platform to biopharma partners for developing cell-based therapies, with a focus on ex-vivo cell therapy manufacturing.
Who is the CEO of MaxCyte Inc.?
Mr. Maher Masoud is the chief executive officer of MaxCyte Inc. (MXCT).
Where is MaxCyte Inc. headquartered?
MaxCyte Inc. (MXCT) is headquartered in Rockville, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.